Management of patients with stroke treated with direct oral anticoagulants
- 6 October 2018
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 265 (12) , 3022-3033
Abstract
Since their market approval, direct oral anticoagulants (DOACs) are being increasingly used for stroke prevention in patients with atrial fibrillation. However, the management of DOAC-treated patients with stroke poses several challenges for physicians in everyday clinical practice, both in the acute setting and in long-term care. This has spurred extensive research activity in the field over the past few years, which we review here.Keywords
This publication has 93 references indexed in Scilit:
- Frailty Consensus: A Call to ActionJournal of the American Medical Directors Association, 2013
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical OutcomeStroke, 2008
- Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human StrokeCirculation, 2003
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1990
- Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study.Stroke, 1983